Trial intelligence / Profile preview

Phase 3 open-label randomized study of selpercatinib versus platinum-pemetrexed with or without pembrolizumab in first-line RET fusion-positive non-small cell lung cancer

MOH_2020-03-03_008746Phase 3Active, not recruiting

Sponsor

ג'ני מלניצנקו

Start

Jan 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1